Search Results 2111-2120 of 18850 for Relapse

  1. MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) - Mayo Clinic

    ... relapse-free for at least 3 years since the diagnosis of the other primary malignancy. Concurrent chronic immunosuppressive treatment either with steroids ...

  2. Pediatrics Clinical Trials - Medical Professionals

    Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...

  3. Obstetrics and Gynecology - Clinical trials

    ... relapse, and subsequent therapy. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine ...

  4. Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas - Mayo Clinic

    All grade 4 gliomas that have relapsed more than once may be included, as the prognosis of multiply recurrent grade 4 glioma patients may not differ based ...

  5. Pemigatinib trial seeks to build on targeted advances in cholangiocarcinoma - Mayo Clinic

    ... relapse within 2 years.4 For patients with unresectable biliary tract cancer, the standard of care is combination therapy with gemcitabine plus cisplatin ...

  6. Rituximab-arrx (intravenous route) - Side effects & uses - Mayo Clinic

    ... relapsed (cancer that has come back), refractory (cancer that did not respond to treatment), previously untreated, or non-progressing non-Hodgkin's lymphoma ...

  7. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    ... relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).

  8. Publications - Ajit H. Goenka, M.D. - Mayo Clinic

    ... relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen View PubMed; Truty MJ, Kendrick ML, Nagorney DM ...

  9. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

    relapse. 8. Any condition that required treatment with steroids or any other immune suppressive drugs within 14 days prior to first dose of study drug. 9 ...

  10. Natalizumab (intravenous route) - Side effects & uses - Mayo Clinic

    This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of flare-ups (relapses) of the disease. Natalizumab ...